Galapagos announces management change
28 Abril 2014 - 12:34AM
Galapagos NV (Euronext: GLPG) announces that Guillaume
Jetten will resign as Chief Financial Officer of Galapagos,
effective 1 May 2014. Laure Verhaegen, Vice President
Finance, will act as interim CFO until a replacement has been
recruited.
Guillaume Jetten joined Galapagos as CFO in June
2009. As CFO, Guillaume has played an important role in
financings, corporate transactions, and daily financial
management. With the recent sale of the service division to
Charles River, he played an important role in the transition of the
Company to now fully focus on the promising pipeline of clinical
molecules and will be leaving Galapagos to pursue other interests,
effective on 1 May 2014.
Laure Verhaegen, head of the finance team, will
act as interim CFO. She joined Galapagos in May 2010 after
more than 10 years in corporate finance, external audit and
controlling in Belgium and Luxembourg. While working in
Corporate Finance for Deloitte, she advised clients across multiple
sectors during their strategic transactions, including mergers
& acquisitions and project financing. Laure Verhaegen
holds a master's degree in Business Engineering obtained at ICHEC
Brussels Management School and a degree in Financial Analysis from
the ABAF.
"Also on behalf of the Board of Directors, I
wish to thank Guillaume for his valuable contribution to
strengthening Galapagos into one of the leading biotechs in
Europe. We wish him the best of luck with his future
endeavors," added Onno van de Stolpe, CEO of Galapagos.
About Galapagos Galapagos (Euronext: GLPG; OTC:
GLPYY) is specialized in novel modes-of-action, with a large
pipeline comprising five Phase 2 studies (two led by GSK), one
Phase 1 study, six pre-clinical, and 20 discovery small-molecule
and antibody programs in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications. In the
field of inflammation, AbbVie and Galapagos signed a worldwide
license agreement whereby AbbVie will be responsible for further
development and commercialization of GLPG0634 after Phase 2B.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for
the treatment of rheumatoid arthritis and potentially other
inflammatory diseases, currently in Phase 2B studies in RA and in
Phase 2 in Crohn's disease. Galapagos has another selective
JAK1 inhibitor in Phase 2 in ulcerative colitis and psoriasis,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program is
currently in a Proof-of-Concept Phase 2 study. GLPG1205 is a
first-in-class molecule that targets inflammatory disorders and has
completed Phase 1. AbbVie and Galapagos signed an agreement
in CF whereby they work collaboratively to develop and
commercialize oral drugs that address two mutations in the CFTR
gene, the G551D and F508del mutation. Potentiator GLPG1837 is
at the pre-clinical candidate stage. Galapagos has 400
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. Further
information at: www.glpg.com
CONTACT
Galapagos NV Onno van de Stolpe, CEO Tel: +31 6
2909 8028 ir@glpg.com
This release may contain forward-looking
statements, including, without limitation, statements containing
the words "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," and
"continues," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based, unless required by law or regulation.
HUG#1780277
Aristocrat (PK) (USOTC:ASCC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Aristocrat (PK) (USOTC:ASCC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024